Allergies
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
UCB PharmaBelgium - Brussels
1 programEvaluation of Treatment Satisfaction in Children With an Allergy and Who Received an AntihistamineN/A1 trial
Active Trials
SandozAustria - Kundl
1 programCetirizine HCl/Pseudoephedrine HCl 5 mg/120 mgPHASE_11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
SandozCetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg
UCB PharmaEvaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine
Clinical Trials (2)
Total enrollment: 4,621 patients across 2 trials
To Demonstrate the Relative Bioavailability of Cetirizine Hydrochloride/Pseudoephedrine Hydrochloride 5 mg/120 mg Extended Release (ER) Tablets Under Fasting Conditions
Start: Jul 2005Est. completion: Jul 200540 patients
Phase 1Completed
NCT00453583UCB PharmaEvaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine
Evaluation of Treatment Satisfaction in Children With an Allergy and Who Received an Antihistamine
Start: Mar 2007Est. completion: Jan 20084,581 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.